From early detection to advanced therapy, prostate cancer care is being reshaped by smarter tools that provide deeper insight and more precise interventions. These advances are enabling clinicians to act sooner, tailor treatment more accurately, and expand options for patients across the disease continuum.
Seeing the unseen: PSMA-PET in prostate cancer
PSMA-PET has transformed prostate cancer imaging, uncovering small or early metastatic deposits that conventional scans often miss. This sharper lens on disease location allows for more precise staging, more tailored treatment plans, and earlier intervention. In practice, this means patients who require systemic therapy are identified sooner and treated appropriately. Once difficult to access, PSMA-PET is now increasingly embedded in routine care, reshaping management at both initial diagnosis and biochemical recurrence.
Decoding risk: Artera AI
Artera’s AI-based test made headlines this past month, marking a new frontier in predictive innovation. As the first FDA-cleared tool of its kind – now included in the NCCN guidelines – it prognosticates long-term outcomes for those with non-metastatic prostate cancer. By integrating digital pathology with clinical data, Artera helps clinicians uncover which patients are most likely to benefit from adding hormone therapy (ADT or abiraterone) to radiation. The result: clearer, more personalised treatment pathways, sparing some patients unnecessary side effects while ensuring others receive the right therapy at the right time.
Following the tumor: ctDNA in real-time
Circulating tumour DNA (ctDNA) could transform how prostate cancer is tracked and managed. By detecting actionable alterations such as BRCA/HRR mutations for PARP inhibitors or emerging resistance mutations like AR mutations, ctDNA can guide more personalised treatment decisions. While ctDNA levels are lower in prostate cancer than in some other tumours, the approach provides a less invasive way to track disease, anticipate changes, and intervene sooner – helping clinicians know more and act with greater confidence.
Hitting harder: Expanding radioligand therapy (RLT)
Radioligand therapy is set to soar, moving into earlier stages of prostate cancer management and multiple RLT agents and combination strategies advancing in development. New classes using actinium-225 and terbium-161 bring highly potent, short-range radiation with distinct efficacy and safety profiles. This evolution promises more therapeutic options, more potential efficacy, more patients who may benefit, and greater complexity in sequencing and clinical decision-making.
The big picture
Together, these innovations illustrate how prostate cancer care is evolving along multiple fronts. Advanced imaging reveals disease earlier, AI-driven tools predict outcomes and guide therapy, ctDNA provides real-time insight into tumour evolution, and next-generation RLT delivers treatment with precision and potency. Smarter detection, smarter prediction, smarter monitoring, and smarter treatment are converging – shaping a future where care is increasingly informed, coordinated, and tailored to each patient’s journey.
Looking ahead
These advances are at different stages in reshaping prostate cancer care, but they raise important questions for current and future practice. As diagnostics, predictive tools, ctDNA monitoring, and RLT continue to evolve, healthcare systems, clinicians, and pharma must navigate new complexities: integrating technologies safely, adapting strategies for increasingly segmented patient populations, and ensuring infrastructure can meet demand. How these challenges are addressed will determine whether the promise of smarter, more personalised care is fully realised.
Considerations for the future
- Implementation challenges: Adoption of innovations can be a rocky road – as we’ve seen with PSMA-PET and RLT. How can pharma support healthcare systems to integrate new technologies efficiently and safely?
- Shifting patient populations: New tools offer fresh ways to segment patients, requiring pharma to remain agile with strategy, forecasting, and trial design.
- AI in clinical decision-making: How do we balance predictive technologies with physician expertise and judgment? What is the evolving role of pharma in supporting physicians’ choices in a world of highly segmented patients and AI-driven decision trees?
- RLT expansion: With a growing number of RLT agents and combination strategies, is there room for all? Will differentiation between agents be sufficient to support adoption, and can healthcare infrastructure keep pace with demand?
If this topic interests you and you’d like to discuss it further, contact our oncology team.